Sunstone LSV Fund II portfolio company VAXIMM AG, a Swiss-German biotech company focused on developing oral T-cell immunotherapies, today announced the appointment of Dr Jarl Ulf Jungnelius, MD, PhD to the newly created position of Chief Medical Officer.

Dr Jungnelius is a seasoned healthcare professional, having spent over thirty years practicing medicine and leading key drug development projects for international pharmaceutical companies, with a strong focus on oncology.



Sunstone Life Sciences Fund II company, Anergis, a company developing proprietary ultra-fast allergy immunotherapy, announced today that it has closed a CHF 5 million financing round extension with existing investors. In addition, the Company is preparing a Phase IIb clinical trial with its lead compound AllerT in patients with birch pollen allergy. The study is designed as a multicenter, double-blind, placebo-controlled, randomized trial to assess the efficacy and tolerability of two dosing regimens of AllerT In Adults with Birch Pollen Allergic Rhinitis/Rhinoconjunctivitis (ATIBAR). ATIBAR is expected to start in fall 2016. With a total of 450 patients, ATIBAR will be the largest field-based trial conducted so far with an ultra-fast allergy treatment for tree allergy.


Baxalta Incorporated (NYSE: BXLT), a global biopharmaceutical leader dedicated to delivering transformative therapies to patients with orphan diseases and underserved conditions, and Symphogen, a private biopharmaceutical company developing recombinant antibodies and antibody mixtures, today announced a broad strategic immuno-oncology collaboration.

F2G Ltd, a UK based antifungal drug discovery and development company, today announced that its novel systemic antifungal product F901318 has been accepted to participate in the European Medicines Agency’s (EMA) Adaptive Pathways pilot programme.

Initiated in March 2014, the Adaptive Pathways pilot program forms part of the EMA’s strategy to provide improved access to new therapies treating serious conditions where there is a high unmet medical need.

Mr Ian Nicholson CEO said “We are delighted to have been accepted into the EMA Adaptive Pathways programme which has the potential to accelerate the approval process for F901318. This will ultimately lead to patients receiving our drug sooner than would normally be the case and will provide treatment options in settings where current choices are inadequate. We would like to thank the EMA and the European HTAs who contributed to the review and collaborative feedback on our proposal at recent EMA/HTA parallel scientific advice.”